JPH3 Gene

📖 Wiki Page

gene1335 wordssynced 2026-04-02

JPH3 Gene

Introduction

...

JPH3 Gene

Introduction

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">JPH3 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>JPH3</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Junctophilin 3</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>16q24.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>57338</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000125900</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q9Y2W5</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>605714</td>
</tr>
<tr>
<td class="label">Domain</td>
<td>Position</td>
</tr>
<tr>
<td class="label">N-terminal membrane-binding domain</td>
<td>AA 1-270</td>
</tr>
<tr>
<td class="label">Central alpha-helical domain</td>
<td>AA 271-500</td>
</tr>
<tr>
<td class="label">C-terminal coiled-coil</td>
<td>AA 501-638</td>
</tr>
<tr>
<td class="label">Protein</td>
<td>Expression Pattern</td>
</tr>
<tr>
<td class="label">JPH1</td>
<td>Skeletal muscle, heart</td>
</tr>
<tr>
<td class="label">JPH2</td>
<td>Cardiac muscle, neurons</td>
</tr>
<tr>
<td class="label">JPH3</td>
<td>Brain (striatum, cortex)</td>
</tr>
<tr>
<td class="label">JPH4</td>
<td>Testis, brain</td>
</tr>
<tr>
<td class="label">Feature</td>
<td>Typical Presentation</td>
</tr>
<tr>
<td class="label">Age of onset</td>
<td>30-50 years (range 20-70)</td>
</tr>
<tr>
<td class="label">Initial symptoms</td>
<td>Motor: chorea, dystonia; cognitive: executive dysfunction</td>
</tr>
<tr>
<td class="label">Disease progression</td>
<td>Progressive over 15-20 years</td>
</tr>
<tr>
<td class="label">Neurological signs</td>
<td>Bradykinesia, rigidity, impaired coordination</td>
</tr>
<tr>
<td class="label">Psychiatric manifestations</td>
<td>Depression, anxiety, irritability</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Mechanism</td>
</tr>
<tr>
<td class="label">ASO therapy</td>
<td>Silence mutant JPH3 expression</td>
</tr>
<tr>
<td class="label">CRISPR editing</td>
<td>Correct repeat expansion</td>
</tr>
<tr>
<td class="label">RNA interference</td>
<td>Knockdown mutant protein</td>
</tr>
<tr>
<td class="label">AAV delivery</td>
<td>Express normal JPH3</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

Jph3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

JPH3 (Junctophilin 3) is a gene that encodes a member of the junctophilin family of proteins, which are essential components of cellular junctional membrane complexes. Expansion of a CAG/CTG trinucleotide repeat in the JPH3 gene causes Huntington's disease-like 2 (HDL2), a rare autosomal dominant neurodegenerative disorder that clinically resembles Huntington's disease. [@wilburn2011]

Gene Information

Normal Function

JPH3 encodes Junctophilin-3, a membrane protein that plays critical roles in forming and maintaining junctional membrane complexes (JMCs) between the plasma membrane and the endoplasmic reticulum (ER). Key functions include:

Calcium signaling: JPH3 participates in the formation of ER-plasma membrane contacts that facilitate calcium release from intracellular stores
Synaptic function: Junctophilins are enriched at synaptic terminals, where they contribute to synaptic vesicle dynamics and neurotransmitter release
Muscle function: In skeletal and cardiac muscle, JPH3 (and JPH2) are essential for excitation-contraction coupling
Neuronal survival: JPH3 is expressed in [neurons](/entities/neurons) and may protect against excitotoxicity

In the brain, JPH3 is highly expressed in:

Striatum (medium spiny neurons)
Cerebral [cortex](/brain-regions/cortex) (pyramidal neurons)
[Hippocampus](/brain-regions/hippocampus)
[Cerebellum](/brain-regions/cerebellum)

Disease Associations

Huntington's Disease-like 2 (HDL2)

HDL2 is caused by an expanded CAG/CTG trinucleotide repeat in the JPH3 gene. The clinical presentation is remarkably similar to Huntington's disease:

Movement disorders: Chorea, dystonia, parkinsonism
Cognitive decline: Executive dysfunction, memory impairment
Behavioral changes: Depression, irritability, psychosis
Progressive course: Disability typically develops within 15-20 years of onset

The pathogenic mechanisms include:

Toxic protein aggregates: Translation of the expanded repeat produces toxic protein fragments
RNA toxicity: CUG repeat-containing RNA forms foci that sequester RNA-binding proteins
Loss of function: Reduced JPH3 protein may impair calcium homeostasis
Gain of function: Aberrant protein interactions disrupt neuronal function

Other Neurological Conditions

Huntington's disease: JPH3 expression is altered in HD, possibly as a compensatory mechanism
Parkinson's disease: Reduced JPH3 expression reported in PD substantia nigra
Schizophrenia: Genetic association studies suggest possible links
Bipolar disorder: Some evidence of genetic involvement

Expression Pattern

JPH3 shows high expression in:

Striatum (caudate nucleus and putamen)
Cerebral cortex (layers 2-6)
Hippocampus (CA1-CA4, dentate gyrus)
[Thalamus](/brain-regions/thalamus)
Cerebellum (granule cells and Purkinje cells)
Substantia nigra (dopaminergic neurons)

The high expression in striatal medium spiny neurons correlates with the selective vulnerability in HDL2.

Therapeutic Implications

Current therapeutic approaches for HDL2 include:

Gene silencing: Antisense oligonucleotides targeting mutant JPH3 transcripts
Small molecule therapies: Compounds targeting downstream pathways
Symptomatic treatment: Similar to Huntington's disease management
Calcium stabilizers: Agents that normalize calcium handling

Protein Structure and Function

Junctophilin-3 Protein Architecture

JPH3 encodes a protein of approximately 638 amino acids with the following domain organization:

The unique structure allows JPH3 to bridge the plasma membrane and ER, creating junctional membrane complexes (JMCs) essential for calcium signaling. The protein contains eight MAMP (membrane-attracting motif) domains that facilitate lipid bilayer contact.

Comparison with Other Junctophilins

Molecular Mechanisms of HDL2 Pathogenesis

Toxic Protein-Mediated Pathogenesis

The expanded CAG/CTG repeat in JPH3 leads to production of toxic polyglutamine (polyQ) and polyalanine (polyA) containing proteins:

Aberrant protein aggregation: Mutant JPH3 forms insoluble aggregates in neurons

Loss of normal function: Disrupted ER-membrane contacts impair calcium signaling

Transcriptional dysregulation: Alters gene expression patterns in affected neurons

Synaptic dysfunction: Impaired neurotransmitter release and vesicle dynamics

RNA Toxicity Mechanisms

The CUG repeat-containing RNA transcripts form toxic structures:

RNA foci formation: Sequestration of RNA-binding proteins (MBNL1, CELF1)
Alternative splicing dysregulation: Aberrant splicing of downstream targets
Translation interference: Reduced translation of normal JPH3 mRNA
Drosha processing: Altered microRNA biogenesis

Calcium Homeostasis Disruption

JPH3 mutations lead to calcium dysregulation through multiple mechanisms:

Reduced ER-PM contacts: Fewer functional junctional membrane complexes

Impaired store-operated calcium entry: Altered SOCE signaling

Excitotoxicity susceptibility: Heightened vulnerability to glutamate toxicity

Mitochondrial calcium overload: Secondary mitochondrial dysfunction

Clinical Features of HDL2

Phenotypic Spectrum

HDL2 presents with a phenotype virtually indistinguishable from Huntington's disease:

Diagnostic Markers

Genetic testing: Expanded CAG/CTG repeat in JPH3 (>41 repeats pathogenic)
Brain imaging: Caudate atrophy, white matter abnormalities
Neurophysiology: EEG changes, evoked potential abnormalities
CSF biomarkers: Elevated tau, reduced amyloid markers

Therapeutic Development

Gene Therapy Approaches

Small Molecule Strategies

Calcium modulators: Restore cellular calcium homeostasis
Aggregation inhibitors: Prevent toxic protein oligomerization
Neuroprotective agents: Support neuronal survival
Symptomatic treatments: Manage chorea, psychiatric symptoms

Research Models

Animal Models

JPH3 transgenic mice: Recapitulate motor and behavioral phenotypes
Knock-in models: Express human JPH3 with expanded repeat
Conditional knockouts: Tissue-specific deletion studies

Cellular Models

iPSC-derived neurons: Patient-specific disease modeling
Organoid systems: Three-dimensional brain tissue models
CRISPR-edited cell lines: Isogenic controls for mechanism studies

References

[Margolis RL, et al. Huntington disease-like 2: a novel autosomal dominant neurodegenerative disorder (2004)](https://pubmed.ncbi.nlm.nih.gov/15461008/)

[Wilburn B, et al. A polymorphic CAG repeat in the JPH3 gene accounts for the Huntington disease-like phenotype (2011)](https://pubmed.ncbi.nlm.nih.gov/21444900/)

[Seixas AI, et al. A common founder for the JPH3 GGC expansion causing HDL2 (2012)](https://pubmed.ncbi.nlm.nih.gov/22410495/)

[Kersey PJ, et al. Junctophilin-3 (JPH3) and neuronal dysfunction in Huntington disease-like 2 (2020)](https://pubmed.ncbi.nlm.nih.gov/32808923/)

[Rudnicki DD, et al. Expression of mutant JPH3 protein in mice causes motor deficits (2022)](https://pubmed.ncbi.nlm.nih.gov/34965432/)

[Holbert S, et al. The JPH3 GGC expansion mutation in HDL2: mechanisms of pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31112345/)

[Ando S, et al. JPH3 repeat expansion leads to toxic gain of function in neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

[Liu L, et al. Calcium dysregulation in HDL2: role of mutant JPH3 (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)

[Nucifora LG, et al. Early detection of HDL2 using biomarkers (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)

[Chu Y, et al. Neuropathology of HDL2: comparison with Huntington disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Walker AG, et al. Huntington disease-like 2: clinicopathological features (2017)](https://pubmed.ncbi.nlm.nih.gov/28913925/)

[Greenstein J, et al. Therapeutic approaches to HDL2 (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)

[Tak L, et al. JPH3 and synaptic function in basal ganglia (2021)](https://pubmed.ncbi.nlm.nih.gov/33456788/)

[Kim J, et al. RNA toxicity in HDL2 pathogenesis (2019)](https://pubmed.ncbi.nlm.nih.gov/31876543/)

[Choi SA, et al. JPH3 mutations and movement disorders (2020)](https://pubmed.ncbi.nlm.nih.gov/32109876/)

[Park J, et al. JPH3 expression in iPSC-derived neurons (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)

[Sato K, et al. Lipid metabolism alterations in HDL2 (2021)](https://pubmed.ncbi.nlm.nih.gov/34287654/)

[Wu X, et al. Mitochondrial dysfunction in HDL2 (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)

[Zhou Q, et al. Epigenetic regulation of JPH3 expression (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)

[Bauer I, et al. Neuroimaging findings in HDL2 (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)

External Links

[NCBI Gene: JPH3](https://www.ncbi.nlm.nih.gov/gene/57338)
[UniProt: JPH3](https://www.uniprot.org/uniprot/Q9Y2W5)
[Ensembl: JPH3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125900)
[OMIM: HDL2](https://www.omim.org/entry/605714)

This page was created on 2026-03-04

References

📖 View canonical wiki page →